FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007341917> ?p ?o ?g. }

• W2007341917 endingPage "1039" @default.
• W2007341917 startingPage "1032" @default.
• W2007341917 abstract "Background: Brimonidine tartrate 0.2%, a selective alpha2—adrenergic receptor agonist, and betaxolol 0.25% suspension, a cardioselective beta1—adrenergic receptor antagonist, are used in the treatment of elevated intraocular pressure (IOP). Objective: This study compared the clinical success and quality-of-life impact of 4 weeks of treatment with brimonidine 0.2% BID compared with those of 4 weeks of treatment with betaxolol 0.25% suspension BID in patients with elevated IOP. Methods: This was a multisite, double-masked, comparative clinical trial in patients with glaucoma or ocular hypertension. Patients were randomly assigned to receive either brimonidine or betaxolol BID. Morning IOP was measured at baseline and at weeks 1 and 4 using Goldmann applanation. Efficacy was determined by reduction in IOP from baseline. Patients experiencing a ≥20% reduction in IOP were considered to have a successful IOP-lowering response. The Glaucoma Disability Index questionnaire was administered at week 4 to assess quality-of-life factors and the incidence of adverse events. Opthalmic examinations were conducted at each visit. Results: One hundred fifty-nine patients were randomized to treatment and completed the study, 81 receiving brimonidine and 78 receiving betaxolol. The majority were white (77.4%) and female (61.6%), and had a diagnosis of open-angle glaucoma (56.0%). After 4 weeks of treatment, both brimonidine and betaxolol effectively lowered IOP from baseline (mean IOP reductions: brimonidine, 5.96 mm Hg; betaxolol, 5.07 mm Hg; P = NS). However, a significantly higher percentage of brimonidine patients (52/81 [64.2%]) than betaxolol patients (37/78 [47.4%]) had a ≥20% reduction in IOP (P = 0.033). No serious adverse events were reported with either study medication. On the quality-of-life assessments, more betaxolol patients reported hyperemia (P = 0.011), and the reported hyperemia was significantly more severe in betaxolol patients (P = 0.009). Conclusions: After 4 weeks of treatment, brimonidine 0.2% BID was clinically successful in significantly more patients and was better tolerated than 4 weeks of treatment with betaxolol 0.25% BID in this population." @default.
• W2007341917 created "2016-06-24" @default.
• W2007341917 creator A5021706786 @default.
• W2007341917 creator A5044257460 @default.
• W2007341917 creator A5085109653 @default.
• W2007341917 creator A5089092854 @default.
• W2007341917 date "2001-07-01" @default.
• W2007341917 modified "2023-09-27" @default.
• W2007341917 title "Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure" @default.
• W2007341917 cites W1987380835 @default.
• W2007341917 cites W1991537059 @default.
• W2007341917 cites W2012408175 @default.
• W2007341917 cites W2020123102 @default.
• W2007341917 cites W2037616034 @default.
• W2007341917 cites W2045223802 @default.
• W2007341917 cites W2050636982 @default.
• W2007341917 cites W2053322657 @default.
• W2007341917 cites W2056397917 @default.
• W2007341917 cites W2063063194 @default.
• W2007341917 cites W2079998382 @default.
• W2007341917 cites W2089177973 @default.
• W2007341917 cites W2090110993 @default.
• W2007341917 cites W2092822107 @default.
• W2007341917 cites W2096806235 @default.
• W2007341917 cites W2097159830 @default.
• W2007341917 cites W2105040157 @default.
• W2007341917 cites W2107608626 @default.
• W2007341917 cites W2166849310 @default.
• W2007341917 cites W2408379065 @default.
• W2007341917 cites W2797597138 @default.
• W2007341917 cites W3137382051 @default.
• W2007341917 doi "https://doi.org/10.1016/s0149-2918(01)80089-8" @default.
• W2007341917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11519768" @default.
• W2007341917 hasPublicationYear "2001" @default.
• W2007341917 type Work @default.
• W2007341917 sameAs 2007341917 @default.
• W2007341917 citedByCount "9" @default.
• W2007341917 countsByYear W20073419172012 @default.
• W2007341917 countsByYear W20073419172019 @default.
• W2007341917 crossrefType "journal-article" @default.
• W2007341917 hasAuthorship W2007341917A5021706786 @default.
• W2007341917 hasAuthorship W2007341917A5044257460 @default.
• W2007341917 hasAuthorship W2007341917A5085109653 @default.
• W2007341917 hasAuthorship W2007341917A5089092854 @default.
• W2007341917 hasConcept C118487528 @default.
• W2007341917 hasConcept C126322002 @default.
• W2007341917 hasConcept C168563851 @default.
• W2007341917 hasConcept C2776521421 @default.
• W2007341917 hasConcept C2778073030 @default.
• W2007341917 hasConcept C2778190193 @default.
• W2007341917 hasConcept C2778527774 @default.
• W2007341917 hasConcept C2779938033 @default.
• W2007341917 hasConcept C2781092963 @default.
• W2007341917 hasConcept C2991803831 @default.
• W2007341917 hasConcept C42219234 @default.
• W2007341917 hasConcept C71924100 @default.
• W2007341917 hasConceptScore W2007341917C118487528 @default.
• W2007341917 hasConceptScore W2007341917C126322002 @default.
• W2007341917 hasConceptScore W2007341917C168563851 @default.
• W2007341917 hasConceptScore W2007341917C2776521421 @default.
• W2007341917 hasConceptScore W2007341917C2778073030 @default.
• W2007341917 hasConceptScore W2007341917C2778190193 @default.
• W2007341917 hasConceptScore W2007341917C2778527774 @default.
• W2007341917 hasConceptScore W2007341917C2779938033 @default.
• W2007341917 hasConceptScore W2007341917C2781092963 @default.
• W2007341917 hasConceptScore W2007341917C2991803831 @default.
• W2007341917 hasConceptScore W2007341917C42219234 @default.
• W2007341917 hasConceptScore W2007341917C71924100 @default.
• W2007341917 hasIssue "7" @default.
• W2007341917 hasLocation W20073419171 @default.
• W2007341917 hasLocation W20073419172 @default.
• W2007341917 hasOpenAccess W2007341917 @default.
• W2007341917 hasPrimaryLocation W20073419171 @default.
• W2007341917 hasRelatedWork W1991537059 @default.
• W2007341917 hasRelatedWork W1994680761 @default.
• W2007341917 hasRelatedWork W2037527826 @default.
• W2007341917 hasRelatedWork W2122440292 @default.
• W2007341917 hasRelatedWork W2264204754 @default.
• W2007341917 hasRelatedWork W2275917273 @default.
• W2007341917 hasRelatedWork W2386071902 @default.
• W2007341917 hasRelatedWork W2612340917 @default.
• W2007341917 hasRelatedWork W3138731514 @default.
• W2007341917 hasRelatedWork W4242914149 @default.
• W2007341917 hasVolume "23" @default.
• W2007341917 isParatext "false" @default.
• W2007341917 isRetracted "false" @default.
• W2007341917 magId "2007341917" @default.
• W2007341917 workType "article" @default.